Physician profile
Kenneth Irwin Levy
NPI 1174712806
$13,555.78
in general payments reported to CMS, 2019-2025
68 companies · $2,203 in 2025
The $2,203 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,755 · 2020: $1,822 · 2021: $1,987 · 2022: $2,268 · 2023: $1,970 · 2024: $1,551 · 2025: $2,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,724.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,556.60 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $934.07 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $922.25 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $918.09 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $862.65 | 2019-2025 | Mounjaro, Kisunla, Zepbound |
| Novo Nordisk INC | $709.25 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $695.18 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $569.62 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $566.38 | 2019-2024 | Spravato |
| Amgen INC. | $506.01 | 2019-2025 | Otezla, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $434.68 | 2023-2025 | Rexulti, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $390.47 | 2022-2025 | Caplyta |
| Astellas Pharma US INC | $359.42 | 2019-2025 | Veozah |
| Sumitomo Pharma America, INC. | $346.66 | 2023-2025 | Gemtesa |
| Eisai INC. | $335.89 | 2020-2025 |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.